Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $53.3000 (-1.71%) ($53.2800 - $53.3000) on Thu. Dec. 24, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.2% (three month average) | RSI | 89 | Latest Price | $53.3000(-1.71%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 26.7% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(61%) ARKK(58%) IWO(58%) IBB(57%) | Factors Impacting TGTX price | TGTX will decline at least -3.1% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-3%) EDOC(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.1% (StdDev 6.2%) | Hourly BBV | -2.4 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $54.12(-1.52%) | 10 Day Moving Average | $51.49(3.52%) | 20 Day Moving Average | $41.37(28.84%) | To recent high | -2.6% | To recent low | 124.7% | Market Cap | $6.75b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |